Bioinvent to present early phase 2a data from ongoing trial with triple combination of bi-1206, rituximab, and calquence in r/r nhl, at ash 2025

Lund, se / access newswire / november 3, 2025 / bioinvent international ab ("bioinvent")(sto:binv)(nasdaq stockholm:binv), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will present new data from the safety run-in portion of its ongoing trial evaluating bi-1206 in combination with rituximab and calquence ® (acalabrutinib) for the treatment of non-hodgkin's lymphoma (nhl) in a poster at the upcoming 2025 american society of hematology (ash) annual meeting, taking place december 6-9, 2025, in orlando, florida. abstract data (as of august 4, 2025) published in the november supplemental issue of blood demonstrates that the triple combination regimen is safe and well-tolerated, with encouraging efficacy data.
ASH Ratings Summary
ASH Quant Ranking